Monica Bertagnolli Net Worth

The estimated Net Worth of Monica Bertagnolli is at least $1.81 mil dollars as of 17 November 2021. Monica Bertagnolli owns over 654 units of Leap Therapeutics Inc stock worth over $1,812 and over the last 3 years he sold LPTX stock worth over $0. In addition, he makes $0 as Independent Director at Leap Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Monica Bertagnolli LPTX stock SEC Form 4 insiders trading

Monica has made over 1 trades of the Leap Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 654 units of LPTX stock worth $1,812 on 17 November 2021.

The largest trade he's ever made was exercising 654 units of Leap Therapeutics Inc stock on 17 November 2021 worth over $1,812. On average, Monica trades about 109 units every 0 days since 2021. As of 17 November 2021 he still owns at least 654 units of Leap Therapeutics Inc stock.

You can see the complete history of Monica Bertagnolli stock trades at the bottom of the page.

Monica Bertagnolli biography

Dr. Monica Bertagnolli M.D. serves as Independent Director of the Company. She has served as a member of our Board since December 2018. Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology at Harvard Medical School, and a member of the Gastrointestinal Cancer and Sarcoma Disease Centers at Dana-Farber/Brigham & Women's Cancer Center, where she collaborates with colleagues in medical oncology, radiation oncology, and pathology to treat cancer patients in a tertiary care setting. Dr. Bertagnolli graduated from Princeton University, and attended medical school at the University of Utah. She trained in surgery at Brigham and Women's Hospital, and was a research fellow at the Dana Farber Cancer Institute (DF/BWCC). Dr. Bertagnolli has a background in laboratory work focusing upon understanding the role of the inflammatory response in epithelial tumor formation. From 1994 to 2011, she led gastrointestinal correlative science initiatives within the National Cancer Institute (NCI) funded Cancer Cooperative Groups, where she facilitated integration of tumor-specific molecular markers of treatment outcome into nationwide clinical cancer treatment protocols. From 2007 to 2018, Dr. Bertagnolli served as the Chief of the Division of Surgical Oncology at DF/BWCC. Dr. Bertagnolli has also had numerous leadership roles in multi-institutional cancer clinical research consortia, and currently serves as the Group Chair of the Alliance for Clinical Trials in Oncology, a nationwide NCI-funded clinical trials group. She is also the Chief Executive Officer of Alliance Foundation Trials, LLC, a not-for-profit corporation that conducts international cancer clinical trials, as well as the Chairman of the Board of Directors of the American Society of Clinical Oncology (ASCO), a 45,000-member organization serving the needs of physicians and other clinicians who care for patients with cancer. Previously, Dr. Bertagnolli was the 2018-2019 President of ASCO.

How old is Monica Bertagnolli?

Monica Bertagnolli is 61, he's been the Independent Director of Leap Therapeutics Inc since 2018. There are 4 older and 6 younger executives at Leap Therapeutics Inc. The oldest executive at Leap Therapeutics Inc is James Cavanaugh, 82, who is the Independent Director.

What's Monica Bertagnolli's mailing address?

Monica's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.

Insiders trading at Leap Therapeutics Inc

Over the last 8 years, insiders at Leap Therapeutics Inc have traded over $0 worth of Leap Therapeutics Inc stock and bought 10,810,588 units worth $40,517,079 . The most active insiders traders include Advisors Llcperceptive Life..., Christopher Mirabelli, eLtd. Bei Gene,. On average, Leap Therapeutics Inc executives and independent directors trade stock every 142 days with the average trade being worth of $1,990,710. The most recent stock trade was executed by Christopher Mirabelli on 26 January 2024, trading 5,000 units of LPTX stock currently worth $13,850.

What does Leap Therapeutics Inc do?

leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.

Complete history of Monica Bertagnolli stock trades at Leap Therapeutics Inc e Natera Inc

Leap Therapeutics Inc executives and stock owners

Leap Therapeutics Inc executives and other stock owners filed with the SEC include:

• Douglas Onsi,
  President, Chief Executive Officer, Director
• Augustine Lawlor,
  Chief Operating Officer
• Christopher Mirabelli,
  Chairman of the Board
• Cynthia Sirard,
  Chief Medical Officer
• Mark O'Mahony,
  Chief Manufacturing Officer
• Nissim Mashiach,
  Independent Director
• Joseph Loscalzo,
  Independent Director
• William Li,
  Independent Director
• Thomas Dietz,
  Lead Independent Director
• James Cavanaugh,
  Independent Director
• Monica Bertagnolli,
  Independent Director
• John W Littlechild,
  Director
• Ventures Ix, L.P.Healthcare...,
  
• Harold R Werner,
  10% owner
• Lilly & Co Eli,
  10% owner
• Patricia A. Martin,
  Director
• Christian M Richard,
  Director
• Richard Schilsky,
  Director
• Advisors Llcperceptive Life...,
  
• Ventures Viii, L.P.Health C...,
  
• Jason Baum,
  Chief Scientific Officer
• Christine Granfield,
  VP, Head of Reg Affairs/Qual
• Ltd. Bei Gene,,
  10% owner